There are 360 resources available
130P - COM701 ± Nivolumab - preliminary results of antitumor activity from a phase 1 study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor.
Presenter: Ryan Sullivan
Session: Poster Display
12P - Multi-omics correlation with clinical outcome in metastatic melanoma patients treated with ipilimumab plus guadecitabine: the NIBIT-M4 study
Presenter: Anna Di Giacomo
Session: Poster Display
131P - First-line HDACi plus Tislelizumab combined with chemotherapy in Advanced NSCLC
Presenter: Lijie Wang
Session: Poster Display
13P - Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in Epithelial Ovarian Cancer co-express CXCL13 and associate with improved survival
Presenter: Vrouyr Bilemjian
Session: Poster Display
133P - Efficacy of Nivolumab Immunotherapy in Non Small-cell Lung Cancer Patients with Bone Metastasis
Presenter: Anchal Mishra
Session: Poster Display
134P - Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory advanced NSCLC patients: a prospective, single arm, two stage study
Presenter: Baohui Han
Session: Poster Display
17P - Using ex vivo organ culture technology to evaluate a T-Cell Bispecific (TCB) CEACAM5 Therapy
Presenter: Adi Zundelevich
Session: Poster Display